Retinoic Acids in Cancer Therapy

Mechanisms of Sensitivity, Resistance, and Methods of Delivery Volume 21
Erscheinungsjahr 2025
ISBN: 978-0-443-22305-1
Verlag: Elsevier Science

Buch, Englisch, 216 Seiten, Format (B × H): 191 mm x 235 mm

Retinoic Acids in Cancer Therapy: Mechanisms of Sensitivity, Resistance, and Methods of Delivery, Volume 21 offers a detailed exploration of how All Trans Retinoic Acid (ATRA) functions to kill cancer cells, as well as the survival mechanisms of certain cells when treated with this drug. This comprehensive book delves into the specific cell pathways and compartments that are involved in the action of retinoic acids (RAs) in inhibiting cell proliferation across various cancers, providing invaluable insights for continued research and improved therapeutic approaches in oncology.

The book comprises 16 chapters that address the molecular structure and biological properties of ATRA, elucidate the mechanisms of resistance to ATRA, and evaluate its efficiency in treating seven different cancers. Additionally, it discusses strategies to enhance ATRA cancer treatment and offers future perspectives on its applications. As a vital resource for health professionals, researchers, and students alike, this volume aims to expand the collective understanding of ATRA's therapeutic potential and inspire the development of new, more effective cancer treatments.

Autoren/Hrsg.

Ghavami, Saeid

Zarrabi, Ali

Cordani, Marco

Fachgebiete

• Naturwissenschaften Biowissenschaften Biowissenschaften

Inhaltsverzeichnis

1. Molecular structure and biological properties of ATRA
2. Cellular and molecular determinants of all-trans retinoic acid sensitivity in different cancers
3. Mechanisms of resistance to ATRA
4. Efficiency of All-Trans Retinoic Acid on Gastric Cancer
5. Efficiency of All-Trans Retinoic Acid on glioblastoma
6. Efficiency of All-Trans Retinoic Acid on lung cancer
7. Efficiency of All-Trans Retinoic Acid on breast cancer
8. Efficiency of All-Trans Retinoic Acid on liver cancer
9. Efficiency of All-Trans Retinoic Acid on stomach cancer
10. Efficiency of All-Trans Retinoic Acid on colon cancer
11. Bioengineered models for investigating ATRA anticancer efficacy and biocompatibility
12. Delivery methods for ATRA
13. Apoptosis, autophagy, and UPR and its impact in ATRA-induced toxicity in cancer cells.
14. ATRA and Cancer Stem Cell Biology
15. OMICs strategies to Improve the ATRA Cancer Treatment
16. Future Perspectives in ATRA applications in Cancer Biology and Nano technology

Über Autor(innen)

Zarrabi, Ali
Ali Zarrabi is an Associate Professor and Principal Investigator in the Faculty of Engineering and Natural Sciences, at Istinye University, in Turkey. He holds a bachelor's degree in Chemical Engineering from Isfahan University of Technology, a master's degree in Chemical Engineering from Sharif University of Technology, and a PhD in Nanobiotechnology from Sharif University of Technology. His group works at the interface of supramolecular chemistry, bioengineering, and medicine to develop approaches for simultaneous diagnosis and treatment of diseases. He has been active as a faculty member for more than 12 years. His current research interests include nanomaterials, nanotheranostics, novel wound dressing and skin patches, and translational nanomedicine. Developing wearable biosensors and diagnostic patches has recently been considered in Zarrabi Lab.

Ghavami, Saeid
Dr. Ghavami completed his undergraduate training MSc and PhD in clinical biochemistry. He is a cancer biologist and his research focusses on the importance of cross talk of three key cellular stress [apoptosis, autophagy and unfolded protein response (UPR)] in regulation of chemotherapy response in cancer cells including Glioblastoma, Rhabdomyosarcoma and non-small cell lung adenocarcinoma. Dr. Ghavami is currently honorary professor and co-founder of Autophagy Research Centre at Shiraz University of Medical Science and Tehran University of Medical Sciences, honorary professor at Katowice School of Technology, Poland. He is associate editor of BBA-Mol Basis of Disease, Molecular Neurobiology, BB Reports and IJMS.